Deals in Depth: April 2010
April's leaders included a $165mm deal that gave Allergan rights to Serenity's late-stage Ser120 for nocturia. Medtronic offered $313mm to buy cardiac device company ATS Medical. Of the nearly $1bn in IPO money, 85% came from one company - Shenzhen Hepalink Pharma. Follow-on dollars on the device side were strong, with two companies bringing over $70mm, while both biopharma and device companies together raised $568mm in private financings.
You may also be interested in...
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.
The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery.